Changes in Hemostasis and Fibrinolysis Rates in the Course of Treatment of New Patients with Pulmonary Tuberculosis after COVID-19 Infection
https://doi.org/10.58838/2075-1230-2025-103-2-6-12
Abstract
The objective: to compare changes in markers of hemostasis and fibrinolysis during the course of treatment in new patients with pulmonary tuberculosis (TB), who suffered from COVID-19 and no COVID-19.
Subjects and Methods. 50 new patients with pulmonary tuberculosis were enrolled in a retrospective study, of them 25 new pulmonary tuberculosis patients had a history COVID-19 (TB/COVID-19 Group) and 25 new pulmonary tuberculosis patients had no COVID-19 (TB Group). The state of hemostasis and fibrinolysis was assessed at four checkpoints: at admission to hospital for treatment and after 1, 2, 3 months of tuberculosis treatment. To assess the relationship between the detected changes and systemic inflammation, C-reactive protein (CRP) was additionally tested.
Results. It was found that new pulmonary tuberculosis in both groups was associated with hypercoagulative shift in the hemostasis system. The incidence of patients with hypercoagulable shift decreased during the course of tuberculosis treatment in both groups. At the same time, the hypercoagulable shift leveled off significantly slower in TB/COVID-19 Group versus TB Group. Inflammatory response persisted in TB/COVID-19 Group throughout the follow-up.
Conclusion. A hypercoagulability shift persisted in new pulmonary tuberculosis patients who had suffered from COVID-19 before and during tuberculosis treatment. This factor requires monitoring of hemostasis and fibrinolysis systems in such patients and, if necessary, pharmacological therapy should be used.
Supporting agencies: The work was carried out according to the plan of Central Tuberculosis Research Institute, Project no. 122041200023-9 Laboratory Aspects of Systemic Inflammatory Response Manifestation in Patients with Tuberculosis and Various Bronchopulmonary Diseases who have had an Infection Caused by SARS-CoV-2.
About the Authors
R. Yu. Abdullaev
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Rizvan Yu. Abdullaev - Doctor of Medical Sciences, Professor, Head of Department of Pathomorphology, Cell Biology and Biochemistry
2 Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-30-23
V. A. Shorokhova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Violetta A. Shorokhova - Candidate of Medical Sciences, Department of Pathomorphology, Cell Biology and Biochemistry
2 Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-30-23
O. G. Komissarova
Central Tuberculosis Research Institute; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Oksana G. Komissarova - Doctor of Medical Sciences, Deputy Director for Research and Treatment Activities, Professor of Phthisiology Department
2 Yauzskaya Alleya, Moscow, 107564
Phone: +7 (499) 785-30-23
References
1. Abdullaev R.Yu., Komissarova O.G., Shorokhova V.A. Systemic inflammation response findings in past COVID-19 patients with newly diagnosed pulmonary tuberculosis. Vestnik Sovremennoy Klinicheskoy Meditsiny, 2023, vol. 16, no. 5, pp. 7-15. (In Russ.) https://doi.org/10.20969/VSKM.2023
2. Komissarova O.G., Abdullaev R.Yu., Shorokhova V.A. Features of lung tuberculosis in patients who have had an infection caused by SARS-COV-2. Modern Problems of Science and Education, 2023, no. 4. (In Russ.) Available: https://science-education.ru/article/view?id=32737 Accessed February 02, 2024
3. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii. Vremennye metodicheskie rekomendatsii. [Provisional guidelines on prevention, diagnostics and treatment of the new coronavirus infection]. 2022, Version 15:15-16. Available: https://minzdrav.gov.ru/ministry/med_covid19 Accessed February 02, 2024
4. Engelen M.M., Vandenbriele C., Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Seminars in Thrombosis and Hemostasis, 2021, vol. 47, no. 4, pp. 362-371.
5. Pasini E., Corsetti G., Romano C., Scarabelli T.M., Chen-Scarabelli C., Saravolatz L., Dioguardi F.S. Serum metabolic profile in patients with Long-Covid (PASC) Syndrome: clinical implications. Front Med (Lausanne), 2021, no. 8, pp. 714426. https://doi.org/10.3389/fmed.2021.714426
6. Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S. et al. Attributes and predictors of long COVID. Nature Medicine, 2021, vol. 27, no. 4, pp. 626-631. https://doi.org/10.1038/s41591-021-01292-y
7. Sy K.T.L., Haw N.J.L., Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infection Diseases (London), 2020, vol. 52, no. 12, pp. 902-907. https://doi.org/10.1080/23744235.2020.180635332808838
8. Tadolini M., Codecasa L.R., García-García J.M. et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. European Respiratory Journal, 2020, vol. 56, no. 1, pp. 2001398. https://doi.org/10.1183/13993003.01398-2020
9. Townsend L., Fogarty H., Dyer A. et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, vol. 19, no. 4, pp. 1064-1070.
10. von Meijenfeldt F.A., Havervall S., Adelmeijer J., Lundström A., Magnusson M., Mackman N., Thalin C., Lisman T. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Advances, 2021, vol. 5, no. 3, pp. 756-759. https://doi.org/10.1182/bloodadvances.2020003968
Review
For citations:
Abdullaev R.Yu., Shorokhova V.A., Komissarova O.G. Changes in Hemostasis and Fibrinolysis Rates in the Course of Treatment of New Patients with Pulmonary Tuberculosis after COVID-19 Infection. Tuberculosis and Lung Diseases. 2025;103(2):6-12. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-2-6-12
Views:
217
Email this article 